O. M. Ipatova

557 total citations
73 papers, 414 citations indexed

About

O. M. Ipatova is a scholar working on Molecular Biology, Pharmacology and Biomaterials. According to data from OpenAlex, O. M. Ipatova has authored 73 papers receiving a total of 414 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Molecular Biology, 16 papers in Pharmacology and 10 papers in Biomaterials. Recurrent topics in O. M. Ipatova's work include Pharmacological Effects of Natural Compounds (14 papers), Nanoparticle-Based Drug Delivery (9 papers) and Lipid Membrane Structure and Behavior (9 papers). O. M. Ipatova is often cited by papers focused on Pharmacological Effects of Natural Compounds (14 papers), Nanoparticle-Based Drug Delivery (9 papers) and Lipid Membrane Structure and Behavior (9 papers). O. M. Ipatova collaborates with scholars based in Russia, United Kingdom and Tajikistan. O. M. Ipatova's co-authors include T. I. Torkhovskaya, A. I. Archakov, A.I. Archakov, Dmitriy Ignatov, K.V. Zolotarev, Petr G. Lokhov, Oxana P. Trifonova, Alexander I. Archakov, E. V. Zemlyanaya and В. Л. Аксенов and has published in prestigious journals such as SHILAP Revista de lepidopterología, Journal of Pharmaceutical and Biomedical Analysis and Pharmaceutics.

In The Last Decade

O. M. Ipatova

68 papers receiving 402 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
O. M. Ipatova Russia 11 161 63 62 43 41 73 414
Neha Atale India 9 163 1.0× 66 1.0× 42 0.7× 31 0.7× 25 0.6× 17 465
Lama Hamadneh Jordan 12 173 1.1× 60 1.0× 97 1.6× 98 2.3× 14 0.3× 50 516
Theodora Mantso United Kingdom 13 232 1.4× 64 1.0× 129 2.1× 63 1.5× 15 0.4× 20 584
Pan Guo China 14 197 1.2× 65 1.0× 66 1.1× 104 2.4× 40 1.0× 26 490
Rizwan Ahmad India 14 181 1.1× 25 0.4× 34 0.5× 20 0.5× 26 0.6× 42 632
María Victoria Aguirre Argentina 15 216 1.3× 69 1.1× 79 1.3× 96 2.2× 13 0.3× 42 602
Fei Peng China 15 203 1.3× 30 0.5× 89 1.4× 70 1.6× 14 0.3× 40 569
Ram Vanam United States 7 251 1.6× 35 0.6× 24 0.4× 19 0.4× 12 0.3× 7 612
Sarika Gupta India 19 315 2.0× 27 0.4× 42 0.7× 39 0.9× 11 0.3× 46 832
J.D. Pipkin United States 16 175 1.1× 67 1.1× 40 0.6× 39 0.9× 25 0.6× 34 529

Countries citing papers authored by O. M. Ipatova

Since Specialization
Citations

This map shows the geographic impact of O. M. Ipatova's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by O. M. Ipatova with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites O. M. Ipatova more than expected).

Fields of papers citing papers by O. M. Ipatova

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by O. M. Ipatova. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by O. M. Ipatova. The network helps show where O. M. Ipatova may publish in the future.

Co-authorship network of co-authors of O. M. Ipatova

This figure shows the co-authorship network connecting the top 25 collaborators of O. M. Ipatova. A scholar is included among the top collaborators of O. M. Ipatova based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with O. M. Ipatova. O. M. Ipatova is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Кухарчук, В. В., А.В. Лисица, O. M. Ipatova, et al.. (2025). Water soluble peroral pharmaceutical form of phosphatidylcholine: experimental and clinical data in combined hyperlipidemia. Annals of the Russian academy of medical sciences. 80(1). 42–48.
2.
Кухарчук, В. В., Andrey Lisitsa, Elena A. Ponomarenko, et al.. (2024). Ultra-small phospholipid nanoparticles in the treatment of combined hyperlipidemia: a randomized placebo-controlled clinical trial. Research in Pharmaceutical Sciences. 19(6). 656–668. 3 indexed citations
3.
Kiselev, Mikhail A., et al.. (2019). Investigation of Nanodrug Phospholipovit by Small-Angle Neutron Scattering. Crystallography Reports. 64(4). 656–661. 1 indexed citations
4.
Korotkevich, Ekaterina, et al.. (2019). Effect of Cell-Penetrating Arginine Peptide on Interaction of Photosensitizer Chlorin e6 Incorporated into Phospholipid Nanoparticles with Tumor Cells. Bulletin of Experimental Biology and Medicine. 167(3). 347–350. 5 indexed citations
5.
Ipatova, O. M., et al.. (2018). Increase of antituberculosis efficiency of rifampicin embedded into phospholipid nanoparticles with sodium oleate. Biomeditsinskaya Khimiya. 64(6). 505–510. 1 indexed citations
6.
Torkhovskaya, T. I., et al.. (2018). Pharmacological targets for dislipidemies correction. Opportunities and prospects of therapeutic usage. Biomeditsinskaya Khimiya. 64(1). 66–83. 1 indexed citations
7.
Torkhovskaya, T. I., et al.. (2018). Pharmacological Targets for Correction of Dyslipidemias. Opportunities and Prospects of Therapeutic Use. Biochemistry (Moscow) Supplement Series B Biomedical Chemistry. 12(2). 96–113. 2 indexed citations
8.
Torkhovskaya, T. I., et al.. (2017). [Influence of doxorubicin inclusion into phospholipid nanoparticles on tumor accumulation and specific activity].. PubMed. 63(1). 56–61. 4 indexed citations
9.
Ignatov, Dmitriy, et al.. (2015). Pharmacological agents and transport nanosystems based on plant phospholipids. Biochemistry (Moscow) Supplement Series B Biomedical Chemistry. 9(3). 205–216. 1 indexed citations
10.
Ipatova, O. M., et al.. (2014). The rifampicin drug delivery system based on phospholipid nanoparticles. Biochemistry (Moscow) Supplement Series B Biomedical Chemistry. 8(2). 177–180. 1 indexed citations
11.
Ignatov, Dmitriy, et al.. (2014). Development of targeted drug delivery system: synthesis of conjugates of address fragment (ra-cooh) with ligand (r-nh2). Biomeditsinskaya Khimiya. 60(6). 713–716. 4 indexed citations
12.
Ipatova, O. M., et al.. (2012). TRANSLATIONAL MEDICINE AS A WAY FROM FUNDAMENTAL BIOMEDICAL SCIENCE TO PUBLIC HEALTH SERVICES. Annals of the Russian academy of medical sciences. 67(6). 57–65. 4 indexed citations
13.
Voskresenskaya, A. A., et al.. (2012). The absorption features of glycyrrhizic acid in composition of drug "phosphogliv". Biomeditsinskaya Khimiya. 58(5). 564–572. 2 indexed citations
14.
Ipatova, O. M., et al.. (2011). The increase of bioavailability and antiinflammatory effect of indomethacin included into phospholipid nanoparticles. Biomeditsinskaya Khimiya. 57(6). 671–676. 7 indexed citations
15.
Ipatova, O. M., et al.. (2010). Bioavailability of oral drug formulations and methods for its improvement. Biomeditsinskaya Khimiya. 56(1). 101–119. 10 indexed citations
16.
Ipatova, O. M., et al.. (2009). Zebrafish as a model system for biomedical studies. Biochemistry (Moscow) Supplement Series B Biomedical Chemistry. 3(4). 343–350. 15 indexed citations
17.
Torkhovskaya, T. I., et al.. (2007). Lysophospholipid receptors in cell signaling. Biochemistry (Moscow). 72(2). 125–131. 27 indexed citations
18.
Ipatova, O. M., et al.. (2006). Sphingolipids and cell signaling: Involvement in apoptosis and atherogenesis. Biochemistry (Moscow). 71(7). 713–722. 20 indexed citations
19.
Коротаева, Т. В., et al.. (2004). Administration of phospholipide hepatoprotective drug Phosphogliv in patients with psoriatic arthritis (preliminary results). Rheumatology Science and Practice. 0(3). 40–40. 1 indexed citations
20.
Ignatov, Dmitriy, et al.. (2003). [A simple method for preparation of 18alpha-glycyrretinic acid ant its derivatives].. PubMed. 29(4). 429–33.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Neha Atale Breakdown of academic impact, for papers by Lama Hamadneh Breakdown of academic impact, for papers by Theodora Mantso Breakdown of academic impact, for papers by Pan Guo Breakdown of academic impact, for papers by Rizwan Ahmad Breakdown of academic impact, for papers by María Victoria Aguirre Breakdown of academic impact, for papers by Fei Peng Breakdown of academic impact, for papers by Ram Vanam Breakdown of academic impact, for papers by Sarika Gupta Breakdown of academic impact, for papers by J.D. Pipkin
Rankless by CCL
2026